Introducing ACUVUE® Abiliti™
A powerful approach to managing the progression of myopia in children.
Myopia is a silent epidemic affecting millions of children around the world—and it’s growing fast.1 Myopia is more than just nearsightedness2-3. It is a progressive disease with a risk of significant complications later in life3-5 that threaten to take away our most treasured sense: Sight.
Our Commitment
Our commitment to fighting this global eye health threat.We marvel at the magic of our eyes, yet we are acutely aware there are many who do not fully experience the wonder of this gift.1As one of the world’s most trusted healthcare brands, we (Johnson & Johnson) believe that changing the trajectory of this disease is our responsibility. We’re determined to find ways to slow the progression of myopia in children, potentially reducing the risk of sight-threatening complications in later life.6We are doing it through our Abiliti™ portfolio. Our ultimate goal is to empower children—like your patients—to see well in their future.
Abiliti™ Approach
The Abiliti™ portfolio is about much more than just vision correction.It’s a comprehensive approach to managing myopia that will include:• Leading with science by continuing to generate new research and evidence• Increasing awareness of myopia as a disease which must be managed• Shaping the future of myopia by changing the trajectory of the disease• Empowering parents, patients, and eye care professionals through partnership, education, and advocacy• Offering a comprehensive portfolio of therapies and treatment supportOur purpose is to slow the progression of the disease itself, versus just treating the symptoms. It may sound ambitious, but it’s built on a strong, well-researched foundation. We believe it will help change the way we look at myopia—one child at a time.
- Our Commitment
- Abiliti™ Approach
Our commitment to fighting this global eye health threat.We marvel at the magic of our eyes, yet we are acutely aware there are many who do not fully experience the wonder of this gift.1As one of the world’s most trusted healthcare brands, we (Johnson & Johnson) believe that changing the trajectory of this disease is our responsibility. We’re determined to find ways to slow the progression of myopia in children, potentially reducing the risk of sight-threatening complications in later life.6We are doing it through our Abiliti™ portfolio. Our ultimate goal is to empower children—like your patients—to see well in their future.
Our Commitment
Abiliti™ Approach
Why change the way you treat myopia?
In the past, eye care professionals saw myopia as a common vision problem, requiring vision correction only. Now, we know that myopia may lead to significant eye-health issues in adulthood3,6—and we are developing treatments that can help slow the progression of the disease itself. The difference is between correcting myopia’s symptoms, and actively managing the disease.This change from myopia correction to myopia management may require a bit more chair time, as well as more time monitoring compliance and progress in your patients. But the benefits are tangible: offering your patients clearer vision today and better eye health in the future. Soon, myopia management will become second nature to you—much like transitioning patients from spectacles to contact lenses.We’ll be there to help you every step of the way, with Master Your Abiliti™ professional support and training through our centers of clinical excellence, marketing materials, and other resources to help your practice transition seamlessly to myopia management.From a practical standpoint, offering myopia management through the Abiliti™ portfolio can help increase your patient base, boost margins and revenue, plus build retention.
Abiliti™ portfolio is a holistic solution built on three main pillars.
see your abiliti™
Abiliti™ will have a comprehensive portfolio designed to manage the progression of myopia in children. Our goal is clearer vision today, and better eye health in the future.In combination with different forthcoming myopia management products, we offer a digital companion called SeeAbiliti™, a personalized mobile app that provides myopia-related lifestyle guidance such as increasing time spent outdoors.Download SeeAbiliti™ App now!Available on:
master your abiliti™
Johnson & Johnson Vision will provide you and your staff with state-of-the-art digital and interactive educational tools along with communication insights to help you, your patients, and their parents successfully navigate the myopia management journey.You’ll receive unparalleled and personalized concierge support, training, and continuing education in slowing the progression of myopia with Master Your Abiliti™ trainings through our clinical centers of excellence. Our evidence-based frameworks and hands-on training provide practical techniques to support you in having high-quality interactions with your patients and their parents. You will also have access to regular conferences, seminars, webinars, and white papers.As a practical matter, our team of myopia clinical consultants will provide you and your staff with intensive training on lens fitting and care, lifestyle interventions, practice management, maximizing your bottom line, marketing, and much more.It’s all designed to help you—as well as your patients and their parents—feel confident that you’re providing them with world-class treatment that adheres to the latest and best practices in myopia management.
share your abiliti™
Johnson & Johnson Vision believes that every child deserves the gift of clear sight. That’s why we’re committed to the ongoing Sight for Kids® program with our non-profit partner Lions Clubs International Foundation. And you can be part of this global effort.A 1-for-1 approach: Each annual purchase of an Abiliti™ product will provide a free comprehensive eye exam to a child in need through Sight for Kids®. An eye exam can detect over 270 different medical conditions7, including myopia, and is important in maintaining overall eye health.
REFERENCES
1. Holden BA, Fricke TR, Wilson DA, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 to 2050. Ophthalmol. 2016;123(5):1036-1042. doi: 10.1016/j.ophtha.2016.01.006.
2. Flitcroft DI et al. IMI–Defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies. Investigative ophthalmology & visual science. 2019;60:M20-30.
3. Flitcroft DI. The complex interactions of retinal, optical and environmental factors in myopia aetiology. Prog Retin Eye Res. 2012;31(6):622-660.
4. Donovan L, Sankaridurg P, Ho A et al Myopia progression rates in urban children wearing single-vision spectacles. OVS 2012;89(1):27-32.
5. Pärssinen O, Kauppinen M. Risk factors for high myopia: a 22-year follow-up study from childhood to adulthood. Acta Ophthalmologica. 2019;97(5):510-518.
6. Haarman AE et al. The Complications of Myopia: A Review and Meta-Analysis. Investigative Ophthalmology & Visual Science. 2020 Apr 9;61:49.
7. Systemic Conditions with Ocular and Visual Manifestations. American Optometric Association. December 2019.
PP2021ABLM4035
2. Flitcroft DI et al. IMI–Defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies. Investigative ophthalmology & visual science. 2019;60:M20-30.
3. Flitcroft DI. The complex interactions of retinal, optical and environmental factors in myopia aetiology. Prog Retin Eye Res. 2012;31(6):622-660.
4. Donovan L, Sankaridurg P, Ho A et al Myopia progression rates in urban children wearing single-vision spectacles. OVS 2012;89(1):27-32.
5. Pärssinen O, Kauppinen M. Risk factors for high myopia: a 22-year follow-up study from childhood to adulthood. Acta Ophthalmologica. 2019;97(5):510-518.
6. Haarman AE et al. The Complications of Myopia: A Review and Meta-Analysis. Investigative Ophthalmology & Visual Science. 2020 Apr 9;61:49.
7. Systemic Conditions with Ocular and Visual Manifestations. American Optometric Association. December 2019.
REFERENCES
